There is currently no established standard of care for preventing locoregional tumor recurrence following resection. The high rate of locoregional lung tumor recurrence leads to a significantly diminished the quality of life and reduced long-term survival for many lung cancer patients. Our technology directly addresses this unmet need and is designed to supplement or replace intravenous chemotherapy or external beam radiation and will become the first ''gold standard'' for preventative therapy against cancer recurrence. Learn More
AcuityBio has been awarded a $1.4M Phase II SBIR grant from the National Cancer Institute.
AcuityBio voted top-three start-up company participating at this year's Massachusetts Life Sciences Innovation Day 2011. link
Mass High Tech names AcuityBio one of "Five You Should Follow". link
AcuityBio's President Jay Schwartz is featured in the April 22-28, 2011 issue (page 3) of the Boston Business Journal. link